References
- Aguilar-Markulis N. V., Beckley S., Priore R., Mettlin C. Auditory toxicity effects of long-term cisdichlorodiammineplatinum. II. Therapy in genito-urinary cancer patients. J Surg Oncol 1981; 16: 111
- Böheim K., Bichler E. Cisplatin-induced ototoxicity: audiometric findings and experimental cochlear pathology. Arch Otorhinolaryngol 1985; 242: 1
- Brown R., Nuss R., Pattersson R., Irey J. Audiometric monitoring of cis-platinum ototoxicity. Gynecol Oncol 1983; 16: 254
- Chapman P. Rapid onset hearing loss after Cisplatinum therapy. J Laryngol Otol 1982; 96: 159
- Fausti S. A., Schechter M. A., Rappaport B. Z., Frey R. H., Mass R. E. Early detection of cisplatin Ototoxicity. Cancer 1984; 53: 224
- Gormley P. E., Bull J. M., LeRoy A. F., Cysyk R. Kinetics of cis-dichlorodiammineplatinum. Clin Pharmacol Ther 1979; 25: 351
- Hartwig S., Pettersson U., Stahle J. Cis-diamminedichloroplatinum: A cytostatic with an ototoxic effect. ORL 1983; 45: 257
- Hayes D. M., Cvitkovic E., Golbey R. B., Scheiner E., Helson L., Krakoff I. H. High dose cis-platinum diammine dichloride. Cancer 1977; 39: 1372
- Helson L., Okonkwo E., Anton L., Cvitkovic E. Cis-platinum ototoxicity. Clin Toxicol 1978; 13: 469
- Higby D. J., Wallace H. J., Albert D., Hollands J. F. Diamminodichloroplatinum in the chemotherapy of testicular tumors. J Urol 1974; 112: 100
- Hill J., Speer R., Loeb E., MacLellan A., Hill N. O., Khan A. Clinical experience with cis-platinous diamminedichloride. Presented at the VII Congress of Chemotherapy, PragueCzechoslovakia, 1971
- Jerlvall L., Dryselius H., Arlinger S. Comparison of manual and computer-controlled audiometry using identical procedures. Scand Audiol 1983; 12: 209
- Laurell G., Borg E. Cis-platin ototoxicity in previously noise-exposed guinea pigs. Acta Otolaryngol (Stockh) 1986; 101: 66
- Lippman A., Helson C., Helson L., Krakoff H. Clinical trials of cis-diamminedichloroplatinum (NSC-119875). Cancer Chemother Rep 1973; 57: 191
- McHaney V. A., Thibadoux G., Hayes F. A., Green A. A. Hearing loss in children receiving cisplatin chemotherapy. J Pediatrics 1983; 102: 314
- Piel I. J., Meyer D., Perfia C. P., Wolfe V. I. Effects of cis-diamminedichloroplatinum (NSC-119875) on hearing function in man. Cancer Chemother Rep 1974; 58: 871
- Reddel R. R., Kefford R. F., Grant J. M., Coates A. S., Fox R. M., Tattersall M. H. N. Ototoxicity in patients receiving cisplatin: Importance of dose and method of drug administration. Cancer Treatment Rep 1982; 66: 19
- Rossof A. H., Slayton R. E., Perlia C. P. Preliminary clinical experience with cis-diammine-dichloro-platinum (II) (NSC-119875, CACP). Cancer 1972; 30: 1451
- Rybak L. Cis-platinum associated hearing loss. J Laryngol Otol 1981; 95: 745
- Spoor A. Presbyacusis values in relation to noise induced hearing loss. Int Audiol 1967; 6: 48
- Taylor D. M. The pharmacokinetics of Cis-diamminedichloroplatinum (II) in animals and man: relation to treatment scheduling. Biochemie 1978; 60: 949
- Vermorken J. B., Kapteíjn T. S., Hart A. A. M., Pinedo H. M. Ototoxicity of dis-diamminedich-loroplatinum (II). Influence of dose, schedule and mode of administration. Eur J Cancer Clin Oncol 1983; 19: 53